Science
US FDA adds strongest warning to Sarepta's Elevidys after fatal liver injuries
The company has grappled with disappointing clinical trial outcomes, safety concerns tied to Elevidys and falling sales.
Subscriber access
Full story for subscribers
Sign in with your subscribed Google account to read the full article.
Checking your access…